Caduet amlodipine and atorvastatin
June 12 2016 by
Ray Sahelian, M.D.

 

Caduet is a prescription drug that combines two medicines, amlodipine besylate and atorvastatin calcium. Amlodipine besylate is used to treat high blood pressure (hypertension), chest pain (angina), or blocked arteries of the heart (coronary artery disease). Atorvastatin is a statin drug used to lower cholesterol levels. Atorvastatin is in a class of drugs called HMG CoA reductase inhibitors. Amlodipine is in a class of drugs called calcium channel blockers. Caduet is used to treat high blood pressure or angina (chest pain) that occurs together with elevated levels of cholesterol or triglycerides.
   I am not a fan of fixed drug combinations. The risk for side effects increases significantly when two drugs are combined.

 

Caduet side effects, danger

Cases of muscle problems and liver problems have been associated with the use of atorvastatin and other similar drugs. Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by a fever or flu-like symptoms, yellowing of the skin or eyes, abdominal pain, unexplained fatigue, dark colored urine, or pale colored stools.

 

Advances in Therapy. 2013. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study). The efficacy and safety of single-pill amlodipine/atorvastatin for reducing blood pressure (BP), low-density lipoprotein cholesterol (LDLC), and predicted 10-year cardiovascular (CV) risk have been demonstrated in low CV risk countries. The Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUET® (amlodipine besylate/atorvastatin calcium; Pfizer, Morrisville, PA, USA; STRONG DUET) study evaluated its clinical utility in Slovakia, one of the highest CV risk regions in Europe. This was a two-phase study involving 100 outpatient cardiologist and internist departments in Slovakia. Phase 1 assessed BP control and CV risk profiles in adults with treated hypertension, and phase 2 was an open-label, multicenter, observational study. In the phase 2 study, patients with treated but uncontrolled hypertension and three or more coronary heart disease risk factors received single-pill amlodipine/atorvastatin (5/10 or 10/10 mg) for 12 weeks. Major outcomes were the percentage of patients achieving target BP (≤140/90 mmHg) and/or LDL-C (≤3 mmol/L) and reductions in predicted 10-year CV risk. Of the 4,672 phase 1 patients, 80.8% had uncontrolled hypertension and 61.4% had dyslipidemia. Of the 1,406 phase 2 patients, 90.3% of patients achieved target BP at week 12, 66.3% achieved target LDL-C, and 60.7% achieved both. The mean 10-year CV risk was reduced by 49% (P < 0.0001); treatment was well-tolerated and safe. Single-pill amlodipine/atorvastatin was associated with significant improvements in BP, LDL-C target attainment, and 10-year CV risk in patients with uncontrolled hypertension in Slovakia.